All In Biotech

Drug Trial Radar · NCT05583552

Study to Evaluate Imetelstat in Patients With High-Risk MDS or AML Failing HMA-based Therapy

A Phase II Study Evaluating the Efficacy and Safety of Imetelstat in Patients With HR Myelodysplastic Syndromes or AML Failing HMA-based Therapy

Last checked: Nov 20, 2026Latest source record: Oct 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

46

Actual

Start

Jun 5, 2023

Primary completion

Mar 27, 2025

Study completion Sep 30, 2025

Sponsor

Sponsor type
Industry
Collaborators
Geron Corporation; Universitätsklinikum Leipzig; Saint-Louis Hospital, Paris, France; QIMR Berghofer Medical Research Institute; Australasian Leukaemia and Lymphoma Group; Groupe Francophone des Myelodysplasies; German Myelodysplastic Syndrome Study Group
First posted
Oct 17, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the efficacy, in terms of hematologic improvement, and safety of imetelstat in participants with high-risk (HR) myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) that is relapsed/refractory to hypomethylating agents (HMAs) treatment. Responding patients are eligible to continue treatment until loss of response/disease progression.

Conditions

  • Myelodysplastic Syndromes
  • Acute Myeloid Leukemia

Interventions

  • Imetelstat sodiumDrug

    Intravenous injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall Hematological Response Rate of Participants After Treatment With ImetelstatTime frame: Up to Week 17 (Visit 9; approximately 17 weeks after first dose).

Locations

11 sites in 3 countries. Site status is shown where the registry gives one.

  • Royal Adelaide Hospital

    Adelaide, Australia

  • Royal Brisbane and Women's Hospitals

    Brisbane, Australia

  • Linear Clinical Research

    Nedlands, Australia

  • CHU Nantes - Hôtel Dieu

    Nantes, France

  • Hôpital Archet 1

    Nice, France

  • Hôpital Saint-Louis

    Paris, France

  • CHU de Toulouse

    Toulouse, France

  • Marien Hospital Düsseldorf

    Düsseldorf, Germany

  • Universität Jena, Medizinische Fakultät

    Jena, Germany

  • Universität Leipzig, Medizinische Fakultät

    Leipzig, Germany

  • Klinikum rechts der Isar

    München, Germany

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.